Prevalence and impact of autoimmune thyroid disease on myasthenia gravis course

Justyna Kubiszewska, Beata Szyluk, Piotr Szczudlik, Zbigniew Bartoszewicz, Małgorzata Dutkiewicz, Maksymilian Bielecki, Tomasz Bednarczuk, Anna Kostera-Pruszczyk

Abstract

Objectives: Autoimmune thyroid diseases (ATDs) frequently accompany myasthenia gravis (MG) and may influence its course. We aimed to determine the association and impact of ATD with early- (<50 years), late-onset MG, or thymoma-MG.

Materials and Methods: Prevalence of ATD was measured in a cross-sectional study of 343 consecutive patients with MG (236 F, 107 M) aged 4–89 years; 83.8% were seropositive, in 2.9%, anti-MuSK antibodies were detected. Concentrations of antithyroid peroxidase antibodies, antithyroglobulin antibodies, antithyrotropin receptor antibodies, and TSH level were measured in all patients. MG clinical course, treatment received, and treatment results were evaluated.

Results: Autoimmune thyroid diseases were diagnosed in 92 (26.8%) of MG patients including 4.4% with Graves (GD), 9% with Hashimoto thyroiditis (HT), and 13.4% with antithyroid antibodies only. GD patients had ocular symptoms more often than patients with antithyroid antibodies or HT (p = .008). ATD prevalence was comparable in MG with early and late onset, while non-ATDs were more frequent in thymoma-MG (p = .049). Immunosuppressive therapy was less frequently needed in the patients with MG and ATD, indirectly indicating milder MG course (p = .005). Risk of myasthenic crisis and the results of treatment did not differ between patients with and without ATD.

Conclusions: Autoimmune thyroid diseases are frequently accompanied by early-and late-onset MG, while thymoma-MG is related to higher risk of non-ATD. Myasthenia coexisting with ATD follows milder course than MG alone.

KEYWORDS
autoimmune thyroid diseases, Graves’ disease, Hashimoto’s thyroiditis, myasthenia gravis

INTRODUCTION

Myasthenia gravis (MG) is a rare antibody-mediated autoimmune disease of the neuromuscular junction, with incidence 0.25–2.00 per 100,000 per year (Verschuuren, Palace, & Erik Gilhus, 2010; Vincent, Palace, & Hilton-Jones, 2001).

In MG, distinct subgroups were defined: early- or late-onset MG (EOMG or LOMG; onset before or after age 50 years, respectively) or...
MG associated with thymoma (T-MG). Autoimmune thyroid diseases (ATDs) are a heterogeneous group of disorders; the three major phenotypes are: (1) patients with hyperthyroidism due to Graves’ disease (GD); (2) patients with hypothyroidism due to Hashimoto’s thyroiditis (HT); and (3) euthyroid patients with positive antithyroid autoantibodies (Ban et al., 2008; Duntas, 2008; Kiessling, Pfughaupt, Ricker, Haubitz, & Mertens, 1981). Prevalence of antithyroid autoimmunity accompanying MG varies in reported series depending on the methods used to identify ATD in the studied cohort from 10% to 20% of MG patients (Christensen et al., 1995; Nakata et al., 2013; Thorlacius, Aarli, Riise, Matre, & Johnsen, 1989).

Hormonal disequilibrium (both hyper- and hypothyroidism) as a cause of MG exacerbation was a subject of numerous case reports (Konno et al., 2009; Sarkhy, Persad, & Tarnopolsky, 2008). There is little data on the impact of ATD on the long-term course of MG.

The aim of our study was to determine the prevalence and impact of ATD on EOMG, LOMG, or thymoma-associated MG in a cohort of Polish patients.

2 | MATERIALS AND METHODS

2.1 | Studied groups

Cross-sectional study of 343 consecutive patients (236 women and 107 men) with MG was performed. The patients were enrolled to the study after informed consent from 1st May 2009 till 31st December 2012 at a single neuromuscular center. Study was approved by the local Ethics Committee. Mean age at MG onset was 39 years (SD: 20.2, range: 2–89) and mean age at enrollment was 47.6 (SD: 23.9, range: 4.5–89.1). MG diagnosis was based on the history, clinical presentation, results of repetitive nerve stimulation test or SFEMG, or serological tests: acetylcholine receptor antibody (ARAb), MuSKAb (RIA, DLD Diagnostica Germany). Data of the patients were collected in the form of questionnaire. The course of the disease including the first symptoms, clinical severity graded with MGFA scale (Jaretzki et al., 2000a, 2000b) at the beginning of the disease, the maximum, and at the last visit.

The diagnosis of GD was confirmed by the presence of: (1) hyperthyroidism, (2) detectable TSH receptor autoantibodies (TRAB), (3) and/or increased radioiodine uptake, (4) and/or the presence of clinically evident orbitopathy (Kuryłowicz et al., 2007; Ploski et al., 2010). None of the GD patients in the study received GCS therapy for Graves’ orbitopathy.

The diagnosis of HT was confirmed by the presence of: (1) hypothyroidism; (2) detectable antithyroid peroxidase antibodies (TPO) antibodies and/or antithyroglobulin antibodies (TG); (3) and/or decreased echogenicity of the thyroid on US examination.

Thyroid antibodies group was defined by the presence of: (1) euthyroidism; (2) detectable anti-TPO and/or anti-TG antibodies; (3) and/or decreased echogenicity of the thyroid in US examination. Nonautoimmune thyroid disease patients had history of hypo- or hyperthyroidism or toxic nodular goiter.

2.2 | Measurement of thyroid autoantibodies and TSH

In all patients, concentrations of anti-TPO, antithyroglobulin antibodies (TG), anti-TSHR (thyrotropin receptor antibodies), and TSH level were measured. TSH level, anti-TPO, anti-TG, and anti-TSHR in the serum samples were determined based on the high-sensitivity technology of the electrochemiluminescence using streptavidin-coated paramagnetic microparticles using automated immunodiagnostic analyzer Elecsys 2010, Roche Diagnostics. The values for specific antibodies were considered abnormal as follows: for anti-TG threshold—above 115 IU ml⁻¹, for anti-TPO—above 34 IU ml⁻¹, for anti-TSHR—above 1.75 IU L⁻¹. Reference values for TSH were 0.27–4.20 μIU ml⁻¹.

2.3 | Statistical analysis

One-tailed binomial test was used to compare observed diagnoses frequencies with expected values based on epidemiological data. Distributions of symptoms were compared using chi-square or Fisher’s test (depending on the expected counts Sarkhy et al., 2008). Ordinal variables (MGFA scores) were compared using Kruskal–Wallis test. Significance level was set at .05.

3 | RESULTS

Two hundred and ten patients were diagnosed with EOMG, 112 with LOMG, 21 had thymoma-MG. A total of 83.8% were seropositive (including all with thymoma-MG); in 6% of tested patients, anti-MuSK antibodies were detected.

Demographic characteristics and prevalence of ATD in MG subgroups are presented in Tables 1 and 2. EOMG was significantly more frequent in females (p < .001). Prevalence of ATD was similar in seropositive and seronegative MG patients. No ATD was diagnosed in a small group of MuSK-MG patients. The age at onset (early- or late-onset MG) had no influence on the ratio of patients with different types of ATD. Thymic hyperplasia was diagnosed with similar

### Table 1 | Demographics and clinical characteristics of myasthenia gravis (MG) subgroups

|                  | Early-onset MG | Late-onset MG | Thymoma-MG |
|------------------|---------------|---------------|------------|
| Age at disease onset (years) | 23.9 (SD 11.4) | 66.3 (SD 9.3) | 45.9 (SD 11.6) |
| Mean disease duration (years) | 11.4 | 3.8 | 4.9 |
| % females | 88.1 | 37.5 | 42.8 |

Early-onset MG was significantly more frequent in females (p < .001).
frequency (45% and 47%) in patients with ATD and in MG without
ATD. There was a tendency in the thymoma prevalence across three
groups (chi-square, $p = .058$). Pairwise comparisons showed that sig-
nificantly higher rates were observed in the group with non- ATDs as
compared with ATD (16% vs. 4%, Fisher’s test, $p = .049$) and MG with-
out ATD (16% vs. 5%, Fisher’s test, $p = .049$).

The clinical characteristics of the studied subgroups and associa-
tion with different MG subgroups are presented in Table 1.

Anti-TPO, anti-TG, and TRAB individual values are presented in
Figure 1. TRAB were detected in 6% of females and none of the male
EOMG, 7.1% females and 2.9% of males with LOMG and none of the
thymoma-MG patients. Comparisons with population reference value
(3%) conducted for each subgroup revealed significant difference in
EOMG female group only ($p = .024$). The prevalence of anti-TPO
and anti-TG antibodies was present in 11.1% females and 8.3% males
($p = .ns$).

### 3.1 Clinical course

At the time of diagnosis, MG was purely ocular in 16.7% of patients
with MG alone, 13.3% with MG and ATD, and 9.7% in MG with non-
ATD ($p = .ns$).

A total of 80% of patients with GD had ocular symptoms, as com-
pared with 67% with TAB and 58% with HT, but similar to patients
with MG only (83%) or MG and non-ATDs (81%) (pairwise comparison,
$p = .ns$). Patients had ptosis and/or diplopia attributable to MG. None
presented with Graves orbitopathy. When MGFA classification of the
severity of MG symptoms in patients with ATD, non-ATD and patients
with no thyroid disease was compared, no significant differences were
demonstrated (data not shown).

Myasthenic crisis occurred in 51 patients: 33 (15.9%) with MG
alone, 6 (21.4%) with non-ATD, and 12 (13.6%) with ATD. The risk was
similar in MG with and without ATD (chi-square, $p = .613$).

Immunosuppressive therapy (either monotherapy with prednisone
or polytherapy) was received by 131 patients with MG only (59.8%), 41

---

**TABLE 2** Characteristics of the studied ATD subgroups and association with different MG groups

|                  | MG without ATD | MG + HT | MG + GD | MG + TAB |
|------------------|----------------|---------|---------|-----------|
| N (% of total group) | 219 (63.8) | 31 (9) | 15 (4.4) | 46 (13.4) |
| Sex (% of female patients) | 63.9 | 67.7 | 100 | 78.1 |
| Age of onset of MG in years (mean, SD) | 37.8 (22.8) | 40.4 (26.1) | 42.6 (19.8) | 42.0 (21.4) |
| MG group (n) (%) | Early-onset MG (210) | 63.8 | 9.0 | 4.3 | 13.8 |
|                  | Late-onset MG (112) | 65.2 | 10.7 | 4.5 | 12.5 |
|                  | Thymoma MG (21) | 57.1 | 0 | 4.8 | 14.3 |

F, female; M, male; SD, standard deviation; MG, myasthenia gravis; ATD, autoimmune thyroid disease; HT, Hashimoto’s thyroiditis; GD, Graves’ disease; TAB, thyroid antibodies.

---

**FIGURE 1** Antithyroid peroxidase antibodies (TPO) (A), antithyroglobulin antibodies (TG) (B), and anti-TSH receptor autoantibodies (TRAB) (C) results in EOMG, LOMG, and thymoma-myasthenia gravis. Individual values are given (log scale)
et al., 1997). In Nakata et al. (2013) study, seropositive patients with the Japanese study (Chen et al., 2013; Kanazawa et al., 2007; Marino and Taiwanese study, while such relationship was not observed in indicating milder course of MG. Similar finding was reported in Italian needed immunosuppressive treatment than patients with MG alone, (Garlepp et al., 1981; Ratanakorn & Vejjajiva, 2002). In the study by Marino et al. (1997), ocular myasthenia was more often observed in patients with ATD. Patients with ocular MG accounted for as much as 40% of those with MG and ATD (Marino et al., 1997). The discrepancies of different studies’ result may be due to several factors including sample size, different diagnostic criteria of ATD, or differences specific to certain populations. Many authors also analyzed the relationship between the MG and thyroid ophthalmopathy. We have not seen Graves’ ophthalmopathy in any of our MG patients. Graves’ ophthalmopathy is reported in approximately 3%–5% of patients with Graves’ disease only (Wiersinga & Bartalena, 2002).

We did not find differences in ATD prevalence between seropositive and seronegative MG (Toth et al., 2006). In Japanese study, other autoimmune disorders occurred more often in seropositive MG patients (24.1%), than in MuSK-Ab-positive patients (8.4%) among which ATDs were predominant (Nakata et al., 2013). In previous studies, less frequent seropositivity in MG with ATD could be attributed either to a small number of patients or (Kanazawa et al., 2007) reflect high number (25%) of thyroma patients in the cohort. Thyroma in our study was related to higher risk of non-ATD (Golden, Robinson, Saldanha, Anton, & Ladenson, 2009; Marino et al., 1997).

Myasthenia gravis severity graded with MGFA scale or occurrence of a myasthenic crisis was similar in our patients with and without ATD, as observed by others (Chen et al., 2013). Similarly, results of treatment in the Kanazawa et al. (2007) study, were not significantly different in patients with and without GBD.

In Meng, Jing, Li, Zhang, and Wang (2016) study, patients with HT and other ATDs were more sensitive to respond to glucocorticoid therapy; there were no significant correlations between the MG remission rate and TSH level, total antibody level, TGAb, and TMAb level.

To conclude: Our study confirms frequent coexistence of thyroid disease in patients with MG and milder course of MG associated with ATD.

ACKNOWLEDGMENTS
The study was financed by the Polish National Centre of Science grant NSC DEC-2011/01/B/NZ5/05346.

DISCLOSURES
The authors declare no financial or other conflict of interest.

CONFLICT OF INTEREST
None declared.
FUNDING INFORMATION
Polish National Centre of Science (grant/award number: NSC DEC-2011/01/B/NZ5/05346).

REFERENCES
Avidan, N., Le Panse, R., Harbo, H. F., Bernasconi, P., Poulas, K., Ginsburg, E., … Miller, A. (2014). VAV1 and BAFF, via NFkappaB pathway, are genetic risk factors for myasthenia gravis. Annals of Clinical and Translational Neurology, 1, 329–339.

Ban, Y., Greenberg, D. A., Davies, T. F., Jacobson, E., Concepcion, E., & Avidan, N., Le Panse, R., Harbo, H. F., Bernasconi, P., Poulas, K., Ginzburg, E., … Miller, A. (2014). VAV1 and BAFF, via NFkappaB pathway, are genetic risk factors for myasthenia gravis. Annals of Clinical and Translational Neurology, 1, 329–339.

Boelaert, K., Newby, P. R., Simmonds, M. J., Holder, R. L., Carr-Smith, J. D., Heward, J. M., … Franklyn, J. A. (2010). Prevalence and relative risk of other autoimmune diseases in subjects with autoimmune thyroid disease. The American Journal of Medicine, 123, 183.e1–e9.

Cardenas-Roldan, J., Rojas-Villarraga, A., & Anaya, J. M. (2013). How do autoimmune diseases cluster in families? A systematic review and meta-analysis. BMC Medicine, 11, 73.

Chen, Y. L., Yeh, J. H., & Chiu, H. C. (2013). Clinical features of myasthenia gravis patients with autoimmune thyroid disease in Taiwan. Acta Neurologica Scandinavica, 27, 170–174.

Christensen, P. B., Jensen, T. S., Tsipourouls, I., Sørensen, T., Kjaer, M., Højer-Pedersen, E., … Lehfeldt, E. (1995). Associated autoimmune diseases in myasthenia gravis. A population-based study. Acta Neurologica Scandinavica, 91, 192–195.

Duntas, L. H. (2008). Environmental factors and autoimmune thyroiditis. Nature Clinical Practice Endocrinology & Metabolism, 4, 454–460.

Gardas, A. (1991). Badania laboratoryjne: Poziom T3, T4, TSH i autoantyko- wcia przeciwtkarczowych w populacji polskiej. Polish Journal of Endocrinology, 42, 353–358.

Garlepp, M. J., Dawkings, R. L., Christiansen, F. T., Lawton, J., Luciani, G., McLeod, J., … Teng, C. S. (1981). Autoimmunity in ocular and generalised myasthenia gravis. Journal of Neuroimmunology, 1, 325–332.

Golden, S. H., Robinson, K. A., Saldanha, I., Anton, B., & Ladenson, P. W. (2009). Clinical review: Prevalence and incidence of endocrine and metabolic disorders in the United States: A comprehensive review. Journal of Clinical Endocrinology and Metabolism, 94, 1853–1878.

Jaretzki, A., III, Barohn, R. J., Ernstoff, R. M., Kaminski, H. J., Keesey, J. C., Penn, A. S., & Sanders, D. B. (2000a). Myasthenia gravis: Recommendations for clinical research standards. Task Force of the Medical Scientific Advisory Board of the Myasthenia Gravis Foundation of America. The Annals of Thoracic Surgery, 70, 327–334.

Jaretzki, A., III, Barohn, R. J., Ernstoff, R. M., Kaminski, H. J., Keesey, J. C., Penn, A. S., & Sanders, D. B. (2000b). Myasthenia gravis: Recommendations for clinical research standards. Task Force of the Medical Scientific Advisory Board of the Myasthenia Gravis Foundation of America. Neurology, 55, 16–23.

Kanazawa, M., Shimohata, T., Tanaka, K., & Nishizawa, M. (2007). Clinical features of patients with myasthenia gravis associated with autoimmune diseases. European Journal of Neurology, 14, 1403–1404.

Keesey, J. C. (2004). Clinical evaluation and management of myasthenia gravis. Muscle and Nerve, 29, 484–505.

Kiessling, W. R., Pflughaupt, K. W., Ricker, K., Haubitz, L., & Mertens, H. G. (1981). Thyroid function and circulating antithyroid antibodies in myasthenia gravis. Neurology, 31, 771–774.

Klein, R., Marx, A., Strobel, P., Schalke, B., Nix, W., & Wilcox, N. (2013). Autoimmune associations and autoantibody screening showed focus recognition in patient subgroups with generalized myasthenia gravis. Human Immunology, 74, 1184–1193.

Kono, S., Ichijo, T., Murata, M., Toda, T., Nakazora, H., Nomoto, N., … Fujioka, T. (2009). Autoimmune polyglandular syndrome type 2 with myasthenia gravis crisis. The Neurologist, 15, 361–363.

Kurylowicz, A., Hiromatsu, Y., Jurecka-Lubieniecka, B., Kula, D., Kowalska, M., Ichimura, M., … Bednarz, K. (2007). Association of NFκB-94ins/del ATTG promoter polymorphism with susceptibility to and phenotype of Graves’ disease. Genes and Immunity, 8, 532–538.

Mao, Z. F., Yang, L. X., Mo, X. A., Qin, C., Lai, Y. R., He, N. Y., … Hackett, M. L. (2011). Frequency of autoimmunity diseases in myasthenia gravis: A systematic review. The International Journal of Neuroscience, 121, 121–129.

Marinò, M., Barbesino, G., Pinchera, A., Manetti, L., Ricciardi, R., Rossi, B., … Chiovato, L. (2000). Increased frequency of euthyroid ophthalmopa- thy in patients with Graves’ disease associated with myasthenia gravis. Thyroid, 10, 799–802.

Marinò, M., Ricciardi, R., Pinchera, A., Barbesino, G., Manetti, L., Chiovato, L., … Mariotti, S. (1997). Mild clinical expression of myasthenia gravis associated with autoimmune thyroid diseases. Journal of Clinical Endo- crinology and Metabolism, 82, 438–443.

Meng, C., Jing, Y., Li, R., Zhang, X. J., & Wang, J. W. (2016). Clinical features of myasthenia gravis with thyroid disease with 106 patients. Zhonghua yi xue za zhi, 96, 854–858.

Nakata, R., Motomura, M., Masuda, T., Shiraishi, H., Tokuda, M., Fukuda, E., … Kawakami, A. (2013). Thymus histology and concomitant auto- immune diseases in Japanese patients with muscle-specific receptor tyrosine kinase-antibody-positive myasthenia gravis. European Journal of Neurology, 20, 1272–1276.

Nauman, J. (1991). Wyniki badań programu MZ-XVII prowadzonych w skali kraju; podsumowanie i wnioski. Polish Journal of Endocrinology, 42, 359–367.

Ploski, R., Brand, O. J., Jurecka-Lubieniecka, B., Franaszczyk, M., Kula, D., Krajewski, P., … Bednarz, K. (2010). Thyroid stimulating hormone receptor (TSHR) intron 1 variants are major risk factors for Graves' disease in three European Caucasian cohorts. PLoS One, 5, e15512.

Ratanakorn, D., & Vejjajiva, A. (2002). Long-term follow-up of myasthenia gravis patients with thyroid disease. Acta Neurologica Scandinavica, 106, 93–98.

Sarkhy, A., Persad, R., & Tarnopolsky, M. (2008). Muscle weakness in a girl with autoimmune hepatitis and Graves’ disease. European Journal of Pediatrics, 168, 241–243.

Simpson, J. F., Westerberg, M. R., & Magee, K. R. (1966). Myasthenia gravis. An analysis of 295 cases. Acta Neurologica Scandinavica, 34, 241–243.

Syper-Kravitz, M., Marai, I., & Shoenfeld, Y. (2005). Coexistence of thy- roid in patients with Graves' disease associated with myasthenia gravis. Endocrinology and Metabolism, 82, 438–443.

Toth, C., McDonald, D., Oger, J., & Brownell, K. (2006). Acetylcholine recep- tor antibodies in myasthenia gravis are associated with greater risk
Vandiedonck, C., Beaurain, G., Giraud, M., Hue-Beauvais, C., Eymard, B., Tranchant, C., ... Garchon, H. J. (2004). Pleiotropic effects of the 8.1 HLA haplotype in patients with autoimmune myasthenia gravis and thymus hyperplasia. *Proceedings of the National Academy of Sciences of the United States of America*, 101, 15464–15469.

Verschuuren, J. J. G. M., Palace, J., & Erik Gilhus, N. (2010). Clinical aspects of myasthenia explained. *Autoimmunity*, 43, 344–352.

Vincent, A., Palace, J., & Hilton-Jones, D. (2001). Myasthenia gravis. *Lancet*, 357, 2122–2128.

Wiersinga, W. M., & Bartalena, L. (2002). Epidemiology and prevention of Graves' ophthalmopathy. *Thyroid*, 12, 855–860.

Yeh, J. H., Kuo, H. T., Chen, H. J., Chen, Y. K., Chiu, H. C., & Kao, C. H. (2015). Higher risk of myasthenia gravis in patients with thyroid and allergic diseases: A national population-based study. *Medicine*, 94, e835.

**How to cite this article:** Kubiszewska, J., Szyluk, B., Szczudlik, P., Bartoszewicz, Z., Dutkiewicz, M., Bielecki, M., Bednarczuk, T. and Kostera-Pruszczyk, A. (2016), Prevalence and impact of autoimmune thyroid disease on myasthenia gravis course. *Brain and Behavior*, 6: 1-6. e00537, doi: 10.1002/brb3.537